ReviewOphthalmology and therapy2023
Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity.
Review in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Network Pharmacology and Experimental Validation Elucidate the Anti-Angiogenic Mechanism of Silibinin.Chemistry & biodiversity · 2026Article
- Oxygen Saturation Targeting and Retinopathy Management in Very Preterm Neonates: An International Survey.Neonatology · 2026Article
- Evaluation of regression, reactivation, retreatment and retinal detachment after injections of three different anti-VEGF drugs for retinopathy of prematurity.Scientific reports · 2026Article
- Retinal Blood Flow Decreases After Treatment with Laser Photocoagulation for Retinopathy of Prematurity.Ophthalmology science · 2026Article
- Retinopathy of Prematurity (ROP): Are We There Yet?Medicina (Kaunas, Lithuania) · 2026Review
- Use of Aflibercept to Treat Retinopathy of Prematurity in Children with Extremely Low Birth Weight.Journal of clinical medicine · 2026Article
- Impact of Intravitreal Ranibizumab on Retinopathy of Prematurity: A Retrospective Analysis.Cureus · 2026Article
- Anti-VEGF versus laser photocoagulation for ROP treatment.Bioinformation · 2026Article
- Modelling direct healthcare costs for screening and treatment of retinopathy of prematurity among infants born at gestational age <24 weeks: findings from a Swedish cohort.BMJ open ophthalmology · 2025Article
- Anti-VEGF Approval and Retinal Photocoagulation for Retinopathy of Prematurity.JAMA ophthalmology · 2025Article
- Targeting ATF6 reduces pathological neovascularization and improves visual outcomes in retinal disease models.Scientific reports · 2025Article
- Retinopathy of prematurity in the era of precision neonatology: from risk stratification to targeted therapies.World journal of pediatrics : WJP · 2025Article
- Retinopathy of Prematurity and MicroRNAs.Biomedicines · 2025Review
- Aflibercept to treat retinopathy of prematurity: need for more research.Journal of perinatology : official journal of the California Perinatal Association · 2025Review
- From tumor microenvironment to ocular hypertension: unraveling the pathogenesis and therapeutic strategies of cancer-related glaucoma.Frontiers in medicine · 2025Review
- Emerging opportunities in ROP therapy: from inhibiting pathological vessel growth to promoting physiological vascularization.Frontiers in medicine · 2025Review
- Ferroptosis related genes in retinopathy of prematurity: Screening for potential pharmacological targets.Molecular vision · 2025Article
- Natural Products in the Treatment of Retinopathy of Prematurity: Exploring Therapeutic Potentials.International journal of molecular sciences · 2024Review
- IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice.Angiogenesis · 2024Article
- Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely low-birthweight infants and includes not only overgrowth of blood vessels, but also insufficient developmental retinal vascular growth in early phases of the disease. Our current treatments of ROP have focused on methods to improve perinatal and prenatal care, reduce premature birth, and prevent early phases of ROP. Nonetheless, addressing vasoproliferation in treatment-warranted eyes remains the mainstay of management. Two main treatment strategies co-exist today: laser treatment, which has been the standard of care since the 1990s, and anti-VEGF injections, which have been used since early reports in 2007 (Travassos et al. in Ophthalmic Surg Lasers Imaging, 38:233-237, https://doi.org/10.3928/15428877-20070501-09 , 2007, Shah et al. in Indian J Ophthalmol 55:75-76, https://doi.org/10.4103/0301-4738.29505 , 2007, Quiroz-Mercado et al. in Semin Ophthalmol 22:109-125, https://doi.org/10.1080/08820530701420082 , 2007).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.